Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 [1] [2].
In Vitro, Anti-CD33 Antibody (OR000283) conjugated to the GSPT1 degrader SMol006 (BMS-986497/ORM-6151) potently kills CD33-expressing AML cell lines and primary relapsed/refractory AML patient blasts with picomolar potency, while showing minimal toxicity to non-cancerous hematopoietic progenitor cells[2].
References:
[1]. Palacino J, et al. ORM-6151: a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for AML.
[2]. Izzo D, et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Ther Adv Med Oncol. 2025;17:17588359241309461. Published 2025 Jan 2.
In Vitro, Anti-CD33 Antibody (OR000283) conjugated to the GSPT1 degrader SMol006 (BMS-986497/ORM-6151) potently kills CD33-expressing AML cell lines and primary relapsed/refractory AML patient blasts with picomolar potency, while showing minimal toxicity to non-cancerous hematopoietic progenitor cells[2].
References:
[1]. Palacino J, et al. ORM-6151: a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for AML.
[2]. Izzo D, et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Ther Adv Med Oncol. 2025;17:17588359241309461. Published 2025 Jan 2.